Cargando…
Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients
Autores principales: | Morse, Michael A, Hobeika, Amy, Gwin, William, Osada, Takuya, Gelles, Jonathan, Rushing, Christel, Niedzwiecki, Donna, Lyerly, H Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652494/ http://dx.doi.org/10.1186/2051-1426-3-S2-P444 |
Ejemplares similares
-
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio
por: Crosby, Erika J, et al.
Publicado: (2020) -
Modern x86 assembly language programming: covers x86 64-bit, AVX, AVX2, and AVX-512
por: Kusswurm, Daniel
Publicado: (2018) -
Optimization of vaccine responses with an E1, E2b, E3 deleted Ad5 vector circumvents pre-existing anti-vector immunity
por: Osada, Takuya, et al.
Publicado: (2009) -
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
por: Morse, Michael A, et al.
Publicado: (2007) -
Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis
por: Feuerherm, A. J., et al.
Publicado: (2019)